{"id":247755,"date":"2026-11-19T07:13:36","date_gmt":"2026-11-19T13:13:36","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/11\/human-protein-car-t-design-avoids-anti-drug-antibodies-and-extends-persistence"},"modified":"2026-11-19T07:13:36","modified_gmt":"2026-11-19T13:13:36","slug":"human-protein-car-t-design-avoids-anti-drug-antibodies-and-extends-persistence","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/11\/human-protein-car-t-design-avoids-anti-drug-antibodies-and-extends-persistence","title":{"rendered":"Human-protein CAR-T design avoids anti-drug antibodies and extends persistence"},"content":{"rendered":"\n<p>A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL \u2014 short for trimeric APRIL (a proliferation-inducing ligand) \u2014 recognizes two proteins on myeloma cells instead of just one. Researchers published their findings in The Lancet.<\/p>\n<p>Multiple myeloma is a cancer of plasma cells, which are immune cells that make antibodies. To create CAR T-cell therapy, scientists modify a patient\u2019s <a href=\"https:\/\/www.news-medical.net\/health\/What-are-T-Cells.aspx\">T cells<\/a> so they can find and attack myeloma cells. Existing CAR T-cell therapies recognize B-cell maturation <a href=\"https:\/\/www.news-medical.net\/health\/What-is-an-Antigen.aspx\">antigen<\/a> (BCMA) on myeloma cells. TriPRIL was engineered by Mass General Brigham researchers to make the CAR-T cells recognize both BCMA and a second protein, transmembrane activator and CAML interactor (TACI). Because the treatment is based on human proteins, the researchers believe it may be less likely to lead to anti-drug antibodies that can reduce the long-term persistence and effects of other CAR-T cells.<\/p>\n<p>\u201c<em>BCMA-targeted CAR T-cell therapy has transformed multiple myeloma treatment, but most patients eventually relapse<\/em>,\u201d said co-senior author Marcela V. Maus, MD, PhD, director of the Mass General Brigham Cancer Institute\u2019s Cellular <a href=\"https:\/\/www.news-medical.net\/health\/What-is-Immunotherapy.aspx\">Immunotherapy<\/a> Program. \u201c<em>TriPRIL adds TACI as a second target, allowing it to find and attack myeloma cells, even if they stop expressing BCMA<\/em>.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL \u2014 short for trimeric APRIL (a proliferation-inducing ligand) \u2014 recognizes two proteins on myeloma cells instead [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11],"tags":[],"class_list":["post-247755","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/247755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=247755"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/247755\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=247755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=247755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=247755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}